Last month, CanSino’s co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV.
The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body.
Researchers said last month that the CanSino vaccine, developed in conjunction with the Chinese army’s study unit, gave the impression of being and induces immune responses in maximum subjects.
Saudi Arabia plans to check the vaccine along with a placebo at 5,000 volunteers and is recently conducting tests in the cities of Riyadh, Dammam and Mecca, Saudi news firm SPA reported Saturday.
The use of any COVID-19 vaccine has not been approved.
CanSino’s first candidate, the first in China to conduct human testing in March, however, other prospective vaccines evolved through Sinovac Biotech and a unit of the China National Pharmaceutical Group (Sinopharm) have already been approved for Phase III testing abroad.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. In case you can’t find any email from our side, please check the spam folder.